Literature DB >> 28078273

Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia.

Lin Fu1, Jinlong Shi2, Jia Liu3, Anqi Liu4, Kailin Xu5, Xiaoyan Ke3.   

Abstract

Entities:  

Year:  2016        PMID： 28078273      PMCID： PMC5222707          DOI： 10.21037/sci.2016.11.13

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN： 2306-9759


× No keyword cloud information.
  9 in total

1.  Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.

Authors:  Hong-Hu Zhu; De-Pei Wu; Jie Jin; Jian-Yong Li; Jun Ma; Jian-Xiang Wang; Hao Jiang; Sai-Juan Chen; Xiao-Jun Huang
Journal:  J Clin Oncol       Date:  2013-10-14       Impact factor: 44.544

2.  Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.

Authors:  Hong-Hu Zhu; Xiao-Jun Huang
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

3.  Quality of life with treated acute promyelocytic leukaemia.

Authors:  Ahmadur Rahman
Journal:  Lancet Oncol       Date:  2014-10-07       Impact factor: 41.316

4.  Outpatient oral treatment for acute promyelocytic leukemia.

Authors:  Hong-Hu Zhu; Xiao-Jun Huang
Journal:  N Engl J Med       Date:  2015-02-26       Impact factor: 91.245

5.  Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.

Authors:  Uwe Platzbecker; Giuseppe Avvisati; Laura Cicconi; Christian Thiede; Francesca Paoloni; Marco Vignetti; Felicetto Ferrara; Mariadomenica Divona; Francesco Albano; Fabio Efficace; Paola Fazi; Marco Sborgia; Eros Di Bona; Massimo Breccia; Erika Borlenghi; Roberto Cairoli; Alessandro Rambaldi; Lorella Melillo; Giorgio La Nasa; Walter Fiedler; Peter Brossart; Bernd Hertenstein; Helmut R Salih; Mohammed Wattad; Michael Lübbert; Christian H Brandts; Mathias Hänel; Christoph Röllig; Norbert Schmitz; Hartmut Link; Chiara Frairia; Enrico Maria Pogliani; Claudio Fozza; Alfonso Maria D'Arco; Nicola Di Renzo; Agostino Cortelezzi; Francesco Fabbiano; Konstanze Döhner; Arnold Ganser; Hartmut Döhner; Sergio Amadori; Franco Mandelli; Gerhard Ehninger; Richard F Schlenk; Francesco Lo-Coco
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

6.  Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

Authors:  Harry J Iland; Marnie Collins; Ken Bradstock; Shane G Supple; Alberto Catalano; Mark Hertzberg; Peter Browett; Andrew Grigg; Frank Firkin; Lynda J Campbell; Amanda Hugman; John Reynolds; Juliana Di Iulio; Campbell Tiley; Kerry Taylor; Robin Filshie; Michael Seldon; John Taper; Jeff Szer; John Moore; John Bashford; John F Seymour
Journal:  Lancet Haematol       Date:  2015-08-20       Impact factor: 18.959

7.  Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

Authors:  Jiong Hu; Yuan-Fang Liu; Chuan-Feng Wu; Fang Xu; Zhi-Xiang Shen; Yong-Mei Zhu; Jun-Min Li; Wei Tang; Wei-Li Zhao; Wen Wu; Hui-Ping Sun; Qiu-Sheng Chen; Bing Chen; Guang-Biao Zhou; Arthur Zelent; Samuel Waxman; Zhen-Yi Wang; Sai-Juan Chen; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

8.  Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.

Authors:  Fabio Efficace; Franco Mandelli; Giuseppe Avvisati; Francesco Cottone; Felicetto Ferrara; Eros Di Bona; Giorgina Specchia; Massimo Breccia; Alessandro Levis; Simona Sica; Olimpia Finizio; Maria Grazia Kropp; Giuseppe Fioritoni; Elisa Cerqui; Marco Vignetti; Sergio Amadori; Richard F Schlenk; Uwe Platzbecker; Francesco Lo-Coco
Journal:  J Clin Oncol       Date:  2014-09-22       Impact factor: 44.544

9.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.

Authors:  Francesco Lo-Coco; Giuseppe Avvisati; Marco Vignetti; Christian Thiede; Sonia Maria Orlando; Simona Iacobelli; Felicetto Ferrara; Paola Fazi; Laura Cicconi; Eros Di Bona; Giorgina Specchia; Simona Sica; Mariadomenica Divona; Alessandro Levis; Walter Fiedler; Elisa Cerqui; Massimo Breccia; Giuseppe Fioritoni; Helmut R Salih; Mario Cazzola; Lorella Melillo; Angelo M Carella; Christian H Brandts; Enrica Morra; Marie von Lilienfeld-Toal; Bernd Hertenstein; Mohammed Wattad; Michael Lübbert; Matthias Hänel; Norbert Schmitz; Hartmut Link; Maria Grazia Kropp; Alessandro Rambaldi; Giorgio La Nasa; Mario Luppi; Fabio Ciceri; Olimpia Finizio; Adriano Venditti; Francesco Fabbiano; Konstanze Döhner; Michaela Sauer; Arnold Ganser; Sergio Amadori; Franco Mandelli; Hartmut Döhner; Gerhard Ehninger; Richard F Schlenk; Uwe Platzbecker
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.